公司资料
Bluejay Diagnostics 股价、新闻与催化剂
- 股票代码:
- BJDX
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
1.02 USD (-2.86%)
收盘价
最后更新: 2026年8月17日
4.49M USD
市值
股价为何变动
As of Aug 17, 2026, BJDX closed down 2.86% at $1.02. No new same-company headline was identified in the current news window.
公司概览
Critical-Care Diagnostics
Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform.
Symphony Platform
Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow.
Symphony IL-6 Test
The lead test measures interleukin-6 as an aid in assessing critically ill patients. The SYMON-II pivotal study enrolled hospitalized patients to support analytical and clinical validation.
U.S. Manufacturing Strategy
Bluejay is establishing domestic manufacturing and supply-chain capacity in preparation for regulatory submission and potential commercialization.
未来催化剂
- Planned FDA 510(k) submission for the Symphony IL-6 test following completion of analytical and clinical validation.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。